The effect of maternal pravastatin therapy on adverse sensorimotor outcomes of the offspring in a murine model of preeclampsia

International Journal of Developmental Neuroscience

Volumn 33, Issue 1, 2014, Pages 33-40

  Carver, Alissa R ^a   Tamayo, Esther ^a   Perez Polo, J Regino ^a   Saade, George R ^a   Hankins, Gary D V ^a   Costantine, Maged M ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Fetal programming; Neuromotor function; Pravastatin; Preeclampsia; Soluble Fms like tyrosine kinase 1

Indexed keywords

ANGIOGENESIS INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREEDING; CLIMBING; CONTROLLED STUDY; COORDINATION; FEMALE; FETUS GROWTH; HYDROPHILICITY; MALE; MOTOR COORDINATION; MOUSE; NONHUMAN; PHENOTYPE; PREECLAMPSIA; PRIORITY JOURNAL; PROGENY; RIGHTING REFLEX; SENSORIMOTOR FUNCTION; VESTIBULAR FUNCTION;

FETAL PROGRAMMING; NEUROMOTOR FUNCTION; PRAVASTATIN; PREECLAMPSIA; SOLUBLE FMS-LIKE TYROSINE KINASE 1;

ANALYSIS OF VARIANCE; ANIMALS; ANTICHOLESTEREMIC AGENTS; DISEASE MODELS, ANIMAL; FEMALE; FETAL DEVELOPMENT; GAIT DISORDERS, NEUROLOGIC; HUMANS; MALE; MICE; POSTURAL BALANCE; PRAVASTATIN; PRE-ECLAMPSIA; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOMOTOR DISORDERS; REFLEX; SEX FACTORS; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84890281271     PISSN: 07365748     EISSN: 1873474X     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2013.11.004     Document Type: Article

References (79)

1. Ahmed A., Singh J., Khan Y., Seshan S.V., Girardi G. A new mouse model to explore therapies for preeclampsia. PLoS ONE 2010, 5(10):e13663.
2. American College of Obstetricians Gynecologists Diagnosis and management of preeclampsia and eclampsia, ACOG Practice Bulletin No. 33. Obstet. Gynecol. 2002, 99:159-167.
3. Anderson S.L. Trajectories of brain development: point of vulnerability or window of opportunity?. Neurosci. Biobehav. Rev. 2003, 27:3-18.
4. Barton J.R., Sibai B.M. Prediction and prevention of recurrent preeclampsia. Obstet. Gynecol. 2008, 112:359-372.
5. Barker D.J., Osmond C. Infant mortality, childhood nutrition, and ischaemic brain disease in England and Wales. Lancet 1986, 1:1077-1081.
6. Berends A.L., de Groot C.J.M., Sijbrands E.J., Sie M.P.S., Benneheij S.H., Pal R., Heydanus R., Oostra B.A., van Duijn C.M., Steegers E.A.P. Shared constitutional risks for maternal vascular-related pregnancy complications and future cardiovascular disease. Hypertension 2008, 51:1034-1041.
7. Cannon T.D., Yolken R., Buka S., Torrey E.F. Decreased neurotrophic response to birth hypoxia in the etiology of Schizophrenia. Biol. Psychiatry 2008, 64:797-802. and the Collaborative Study Group on the Perinatal Origins of Severe Psychiatric Disorders.
8. Carver A.R., Costantine M., Tamayo E., Yin H., Perez-Polo J.R., Saade G. Altered fetal brain programming in a preeclampsia-like mouse model and its prevention by prenatal treatment with pravastatin. Am. J. Obstet. Gynecol. 2013, 208:S41.
9. Costantine M.M., Rea C.H., Tamayo E., Ghulmiyyah L., Wen T., Perez-Polo J.R., Hankins G.D.V., Saade G. Susceptibility to hypoxic-ischemic injury in rat pups born to mothers with preeclampsia induced by sflt-1 overexpression. Am. J. Obstet. Gynecol. 2008, 199:S40.
10. Costantine M.M., Yin H., Tamayo E., Rea C.H., Chiossi G., Perez-Polo J.R., Saade G. The effect of preeclampsia induced by overexpression of sFlt-1 in mice on determinants of fetal neuronal migration. Am. J. Obstet. Gynecol. 2009, 201:S282-S283.
11. Costantine M.M., Tamayo E., Lu F., Bytautiene E., Longo M., Hankins G.D.V., Saade G.R. Using pravastatin to improve the vascular reactivity in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Obstet. Gynecol. 2010, 116(1):114-120.
12. Edison R.J., Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am. J. Med. Genet. A 2004, 131(3):287-289.
13. Ehrenstein V., Rothman K.J., Pederson L., Hatch E.E., Sorensen H.T. Pregnancy-associated hypertensive disorders and adult cognitive function among Danish conscripts. Am. J. Epidemiol. 2009, 170(8):1025-1031.
14. Elahi M.M., Cagampang F.R., Anthony F.W., Curzen N., Ohri S.K., Hanson M.A. Statin treatment in hypercholesterolemic pregnant mice reduces cardiovascular risk factors in their offspring. Hypertension 2008, 51:939-944.
15. Ferrari D.C., Nesic O.B., Perez-Polo J.R. Oxygen resuscitation does not ameliorate neonatal hypoxia/ischemia-induced cerebral edema. J. Neurosci. Res. 2010, 88(9):2056-2065.
16. Fox K.A., Longo M., Tamayo E., Kechichian T., Bytautiene E., Hankins G.D.V., Saade G.R., Costantine M.M. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am. J. Obstet. Gynecol. 2011, 205:366e1-366e5.
17. Gabory A., Roseboom T.J., Moore T., Moore L.G., Junien C. Placental contribution to the origins of sexual dimorphism in health and diseases: sex chromosomes and epigenetics. Biol. Sex Differ. 2013, 4:5.
18. Ganu R.S., Harris R.A., Collins K., Aagaard K.M. Early origins of adult disease: approaches for investigating the programmable epigenome in humans, nonhuman primates, and rodent. ILAR J. 2012, 53:306-321.
19. Geelhoed J.J.M., Fraser A., Tilling K., Benfield L., Smith G.D., Sattar N., Nelson S.M., Lawlor D.A. Preeclampsia and gestational hypertension are associated with childhood blood pressure independently of family adiposity measures: the Avon longitudinal study of parents and children. Circulation 2010, 122:1192-1199.
20. Gluckman P.D., Hanson M.A., Cooper C., Thornburg K.L. Effect of in-utero and early-life conditions on adult health and disease. N. Engl. J. Med. 2008, 359:61-73.
21. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
22. Hatanaka T. Clinical pharmacokinetics of pravastatin. Clin. Pharmacokinet. 2000, 39:397-412.
23. Heyser C.J. Assessment of developmental milestones in rodents. Curr. Protoc. Neurosci. 2008, 18. (Chapter 8, Unit 8).
24. Hill C.A., Fitch R.H. Sex differences in mechanisms and outcome of neonatal hypoxia-ischemia in rodent models: implications for sex-specific neuroprotections in clinical neonatal practice. Neurol. Res. Int. 2012, 867531:1-9.
25. Hoglund K., Blennow K. Effect of HMG-CoA reductase inhibitors on β-amyloid peptide levels: implications for Alzheimer's disease. CNS Drugs 2007, 21(6):449-462.
26. Holmberg E., Zhang S., Sarmiere P.D., Kluge B.R., White J.T., Doolen S. Statins decrease chondroitin sulfate proteoglycan expression and acute astrocyte activation in central nervous system injury. Exp. Neurol. 2008, 214(1):78-86.
27. Hosokawa A., Bar-Oz B., Ito S. Use of lipid lowering agents (statin) during pregnancy. Can. Fam. Phys. 2003, 49:747-749.
28. Infante S.K., Harriett C.R., Perez-Polo J.R. Transgenerational effects of neonatal hypoxia-ischemia in progeny. Int. J. Dev. Neurosci. 2013, 31(6):398-405.
29. Jayet P.Y., Rimoldi S.F., Stuber T., Salmon C.S., Hutter D., Rexhaj E., Thalmann S., Schwab M., Turini P., Sartori-Cucchia C., Nicod P., Villena M., Allemann Y., Scherrer U., Sartori C. Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsia. Circulation 2010, 122:488-494.
30. Kajantie E., Eriksson J.G., Osmond C., Thornburg K., Barker D.J.P. Pre-eclampsia is associated with increased risk of stroke in the adult offspring. Stroke 2009, 40:1176-1180.
31. Kazmin A., Garcia-Bournissen F., Koren G. Risk of statin use during pregnancy: a systematic review. J. Obstet. Gynaecol. Can. 2007, 29:906-908.
32. Kumar A., Sharma N., Gupta A., Kalonia H., Mishra J. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms. Brain Res. 2012, 1471:13-22.
33. Kumasawa K., Ikawa M., Kidoya H., Hasuwa H., Saito-Fujita T., Morioka Y., Takakura N., Kimura T., Okabe M. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(4):1451-1455.
34. Lalonde R., Strazielle C. Sensorimotor learning in Dab1scm (scrambler) mutant mice. Behav. Brain Res. 2011, 218:350-352.
35. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F., Schisterman E.F., Thadhani R., Sachs B.P., Epstein F.H., Sibai B.M., Sukhatme V.P., Karumanchi S.A. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004, 350:672-683.
36. Li H., Pin S., Zeng Z., Wang M.M., Andreasson K.A., McCullough L.D. Sex differences in cell death. Ann. Neurol. 2005, 58(2):317-321.
37. Li A., Lv S., Yu Z., Zhang Y., Ma H., Zhao H., Piao H., Li S., Zhang N., Sun C. Simvastatin attenuates hypomyelination induced by hypoxia-ischemia in rats. Neurol. Res. 2010, 32(9):945-952.
38. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am. J. Cardiol. 2005, 96(5A):24F-33F.
39. Liao J.K., Farmer J.A. Statins as adjunctive therapy in the management of hypertension. Curr. Atheroscler. Rep. 2010, 12:349-354.
40. Longo M., Jain V., Vedernikov Y.P., Bukowski R., Garfield R.E., Hankins G.D., Anderson G.D., Saade G.R. Fetal origins of adult vascular dysfunction in mice lacking endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 288:R1114-R1121.
41. Lu F., Bytautiene E., Tamayo E., Gamble P., Anderson G.D., Hankins G.D.V., Longo M., Saade G.R. Gender-specific effect of over-expression of sFlt-1 in pregnant mice on fetal programming of blood pressure in the offspring later in life. Am. J. Obstet. Gynecol. 2007, 197:418e1-418e5.
42. Lu F., Longo M., Tamayo E., Maner W., Al-Hendy A., Anderson G., Hankins G.D.V., Saade G. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am. J. Obstet. Gynecol. 2007, 96(396):e1:396-e:397.
43. Machon R.A., Mednick S.A., Huttunen M.O. Adult major affective disorder after prenatal exposure to an influenza epidemic. Arch. Gen. Psychiatry 1997, 54:322-328.
44. Mahmood A., Goussev A., Kazmi H., Qu C., Lu D., Chopp M. Long-term benefits after treatment of traumatic brain injury with simvastatin in rats. Neurosurgery 2009, 65(1):187-192.
45. Mann J.R., McDermott S., Bao H., Hardin J., Gregg A. Pre-eclampsia, birth weight, and autism spectrum disorders. J. Autism Dev. Disord. 2010, 40:548-554.
46. Mann J.R., McDermott S. Are maternal genitourinary infection and pre-eclampsia associated with ADHD in school-aged children?. J. Atten. Disord. 2011, 15(8):667-673.
47. Many A., Fattal A., Leitner Y., Kupfermine M.J., Harel S., Jaffa A. Neurodevelopmental and cognitive. Assessment of children born growth restricted to mothers with and without preeclampsia. Hypertens. Pregnancy 2003, 22(1):25-29.
48. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., Libermann T.A., Morgan J.P., Sellke F.W., Stillman I.E., Epstein F.H., Sukhatme V.P., Karumanchi S.A. Excess placental soluble fms-like tyrosine kinase 1 (sFlt) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003, 111(5):649-658.
49. McCarthy M.M., Auger A.P., Bale T.L., de Vries G.J., Dunn G.A., Forger N.G., Murray E.K., Nugent B.M., Schwarz J.M., Wilson M.E. The epigenetics of sex differences in the brain. J. Neurosci. 2009, 29(41):12815-12823.
50. McTaggart F., Buckett L., Davidson R., Holdgate G., McCormick A., Schneck D., Smith G., Warwick M. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. 2001, 87:28-32B.
51. Mooradian A.D., Haas M.J., Batejko O., Hovsepyan M., Feman S.S. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes 2005, 54:2977-2982.
52. Munn E., Bunning M., Prada S., Bohlen M., Crabbe J.C., Wahlsten D. Reversed light-dark cycle and cage enrichment effects on ethanol-induced deficits in motor coordination assessed in inbred mouse strains with a compact battery of refined tests. Behav. Brain Res. 2011, 224:259-271.
53. Nanovskaya T.N., Patrikeeva S.L., Paul J., Costantine M.M., Hankins G.D., Ahmed M.S. Transplacental transfer and distribution of pravastatin. Am. J. Obstet. Gynecol. 2013, 209:373.e1-373.e5.
54. Ofori B., Rey E., Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br. J. Clin. Pharmacol. 2007, 64(4):496-509.
55. Ounsted M., Cockburn J., Moar V.A., Redman C.W.G. Maternal hypertension with superimposed preeclampsia: effects on child developmenta at 7 1/2 years. Br. J. Obstet. Gynecol. 1983, 90:644-649.
56. Paintlia A.S., Paintlia M.K., Singh I., Skoff R.B., Singh A.K. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 2009, 57(2):182-193.
57. Peacock J.L., Marston L., Marlow N., Calvert S.A., Greenough A. Neonatal and infant outcome in boys and girls born very prematurely. Pediatr. Res. 2012, 7(3):305-310.
58. Qing X., Redecha P.B., Burmeister M.A., Tomlinson S., D'Agati V.D., Davisson R.L., Salmon J.E. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2011, 79(3):331-339.
59. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science 2005, 308:1592-1594.
60. Ropers H.H., Hamel B.C.J. X-linked mental retardation. Nat. Rev. Genet. 2005, 6(1):46-57.
61. Saad A.F., Kechichian T., Yin H., Sbrana E., Longo M., Wen M., Tamayo E., Hankins G.D.V., Saade G.R., Costantine M.M. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod. Sci. 2013, (in press).
62. Santos M.S., Joles J.A. Early determinants of cardiovascular disease. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 26:581-597.
63. Sacco R.L., Liao J.K. Drug insight: statins and stroke. Nat. Clin. Pract. Cardiovasc. Med. 2005, 2(11):576-584.
64. Siedman D.S., Laor A., Gale R., Stevenson D.K., Mashiachi S., Danon Y.L. Pre-eclampsia and offspring's blood pressure, cognitive ability, and physical development at 17-years of age. Br. J. Obstet. Gynecol. 1991, 98:1009-1014.
65. Singh J., Ahmed A., Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 2011, 58:716-724.
66. Spinillo A., Iasci A., Capuzzo E., Egbe T.O., Colonna L., Fazzi E. Two-year infant neurodevelopmental outcome after expectant management and indicated preterm delivery in hypertensive pregnancies. Acta Obstet. Gynecol. Scand. 1994, 73:625-629.
67. Stanley J.L., Lincoln R.J., Brown T.A., McDonald L.M., Dawson G.R., Reynolds D.S. The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination defects induced by benzodiazepines. J. Psychopharmacol. 2005, 19(3):221-227.
68. Suren P., Bakken I.J., Aase H., Chin R., Gunnes N., Lie K.K., Magnus P., Reichborn-Kjennerud T., Schjolberg S., Oyen A.S., Stoltenberg C. Autism spectrum disorder, ADHD, epilepsy, and cerebral palsy in Norwegian children. Pediatrics 2012, 130:e152-e158.
69. Taguchi N., Rubin E.T., Hosokawa A., Choi J., Ying A.Y., Moretti M.E., Koren G., Ito S. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod. Toxicol. 2008, 26(2):175-177.
70. Tanase H., Hirose K. Reproduction study of pravastatin sodium administered prior to and in the early stages of pregnancy in rats [English abstract]. Yakuri to Chiryo 1987, 15:4975-4982.
71. Van Schie P.E.M., Rep A., Ganzevoort W., de Groot L., Wolf H., van Wassenaer A.G., de Vries J.I.P. General movements in infants born from mothers with early-onset hypertensive disorders of pregnancy in relation to one year's neurodevelopmental outcome. Early Hum. Dev. 2008, 84:605-611.
72. van Wassenaer A.G., Westera J., van Schie P.E.M., Houtzager B.A., Cranendonk A., de Groot L., Ganzevoort W., Wolf H., de Vries J.I.P. Outcome at 4.5 years of children born after expectant management of early-onset hypertensive disorders of pregnancy. Amer. J. Obstet. Gynecol. 2011, 204:510e1-510e9.
73. Wang H., Lynch J.R., Song P., Yang H.J., Yates R.B., Mace B., Warner D.S., Guyton J.R., Laskowitz D.T. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp. Neurol. 2007, 206(1):59-69.
74. Whitehouse A.J., Robinson M., Newnham J.P., Pennell C.E. Do hypertensive diseases of pregnancy disrupt neurocognitive development in offspring?. Paediatr. Perinat. Epidemiol. 2012, 26(2):101-108.
75. Woollett L.A. Maternal cholesterol in fetal development: transport of cholesterol from the maternal to the fetal circulation. Am. J. Clin. Nutr. 2005, 82:1155-1161.
76. Woollett L.A. Review: transport of maternal cholesterol to the fetal circulation. Placenta 2011, 32(Suppl.):S218-S221.
77. Zhang L., Zhang Z.G., Chopp M. The neurovascular unit and combination treatment strategies for stroke. Trends Pharmacol. Sci. 2012, 33(8):415-422.
78. Zhao X., Jones S.M., Yamoah E.N., Lundberg Y.W. Otoconin-90 deletion leads to imbalance but normal hearing: A comparison with other otoconia mutants. Neuroscience 2008, 153(1):289-299.
79. Zhu C., Xu F., Wang X., Shibata M., Uchiyama Y., Blomgren K., Hagberg H. Different apoptotic mechanisms are activated in male and female brains after neonatal hypoxia-ischaemia. J. Neurochem. 2006, 96(4):1016-1027.